Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.